IntelliPharmaCeutics Intl (NASDAQ:IPCI) (TSE:I) received a $2.00 price target from analysts at Maxim Group in a research note issued on Friday. The brokerage currently has a “buy” rating on the stock. Maxim Group’s price objective would indicate a potential upside of 166.70% from the stock’s current price.
A number of other equities analysts have also issued reports on the stock. HC Wainwright began coverage on shares of IntelliPharmaCeutics Intl in a research report on Friday, January 19th. They set a “buy” rating and a $2.50 target price on the stock. Zacks Investment Research lowered shares of IntelliPharmaCeutics Intl from a “hold” rating to a “sell” rating in a research report on Wednesday, January 17th. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and two have given a buy rating to the company. The company presently has a consensus rating of “Hold” and a consensus target price of $2.40.
Shares of IntelliPharmaCeutics Intl (IPCI) traded up $0.01 during trading on Friday, hitting $0.75. 213,919 shares of the stock were exchanged, compared to its average volume of 548,486. IntelliPharmaCeutics Intl has a twelve month low of $0.70 and a twelve month high of $2.92. The firm has a market capitalization of $26.03, a PE ratio of -2.21 and a beta of 1.06.
IntelliPharmaCeutics Intl Company Profile
Intellipharmaceutics International Inc is a Canada-based pharmaceutical company engaged in the research, development and manufacture of controlled-release and targeted-release oral solid dosage drugs. Its Hypermatrix technology is a multidimensional controlled-release drug delivery platform that is applied to the development of a range of existing and new pharmaceuticals.
Receive News & Ratings for IntelliPharmaCeutics Intl Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IntelliPharmaCeutics Intl and related companies with MarketBeat.com's FREE daily email newsletter.